Leading the way for over 30 years
Throughout our history as an innovator in autoimmune diagnostics, we’ve been driven by a simple mission: help labs improve the way patients with autoimmune diseases are diagnosed, monitored, and treated. Since 1987, we’ve continually worked with clinical researchers to develop new biomarkers for more accurate testing. We also collaborate with experts in automation to deliver more efficient systems that help clinical labs improve their testing processes.
Inova, integral part of Werfen since 2008
Werfen is a growing, privately held corporation that was founded in 1966 in Barcelona, Spain.
We are a worldwide leader in in vitro diagnostics (IVD) in the specialties of Hemostasis, Acute Care Diagnostics and Autoimmunity.
At present, we operate directly in nearly 30 countries and in more than 100 territories through distributors. Our R&D and production centers are located in the United States and Europe. In 2018, our consolidated sales were 1,359M€ and we had an average workforce of 5,155 people.
With these core pillars at the center of our shared values within Werfen, we also strive to nurture the following qualities in all of our team members.
DELIVERY OF RESULTS
Quality & Excellence, With A Customer Focus
We are thoroughly committed to accomplishing our mission and strategic long-term goals. We are dedicated to exceeding our customers’ and stakeholders’ expectations and going the extra mile that sets us apart from others.
Leadership and management
Teamwork Meets Innovation
We are dedicated to solid leadership and collaborative teamwork that allows us to carry out the strategy and the mission of our company in a purposeful way. We continue to invest in innovation, as it is the catalyst for the growth and success of our business and the key to our competitive advantage.
Honesty, Humility, and Respect for People
We always live up to our words. We say what we mean and we mean what we say. We are direct and straightforward and we deliver according to the expectations we have generated, allowing us to build trust and credibility among our customers and stakeholders.
Inova Diagnostics Receives FDA Clearance for Test to Detect Antibodies to HMGCR
Inova Diagnostics, a world leader in autoimmune disease diagnostic systems and reagents for the clinical laboratory, is pleased to announce the clearance of QUANTA Flash® HMGCR by the US Food and Drug Administration (FDA). HMGCR is a marker exclusively available from Inova Diagnostics, and is one of 30 FDA-cleared assays available on BIO-FLASH®, a random access chemiluminescent system. QUANTA Flash HMGCR aids in the diagnosis of idiopathic inflammatory myopathy (IIM). IIM is a group of conditions that affect the skeletal muscles which can result in progressive muscle weakness, in some cases leading to tissue necrosis and disability.
OUR LATEST INNOVATIONS
QUANTA-Lyser 3000 is a high throughput EIA/IFA that give you the ability to complete your workload faster with less hands-on time. That equates to maximum efficiency with increased productivity, all while safeguarding reagent and patient traceability to ensure integrity of results.
It All Starts With People
Our talent is, without question, our most important asset. Our employees are the face of Inova, and they represent our values in their day-today interactions.
Please contact us directly via email, telephone, or with the following form.
TOLL FREE PHONE: